JAMA Neurol:MOG-IgG脊髓炎特征研究

2018-12-24 zhangfan MedSci原创

MOG-IgG相关疾病的早期表现为脊髓炎,其中最常见的为急性弛缓性脊髓炎,疑似MOG-IgG人群因接受相应的临床及影像学检查

识别髓鞘少突胶质细胞糖蛋白自身抗体型(MOG-IgG) 患者临床特点,是早期准确诊断和治疗的关键。近日研究人员就MOG-IgG型脊髓炎的临床、影像学及预后特点进行考察,并与水通道蛋白-4-IgG(AQP4-IgG) 脊髓炎和多发性硬化(MS)进行比较。

54名MOG-IgG阳性脊髓炎患者参与研究,入选标准包括临床脊髓炎症状、MOG-IgG阳性以及病历可获得,同时招募46名AQP4-IgG以及26名MS患者。研究的主要终点包括Rankin评分、辅助行走需求以及脊柱磁共振成像。

MOG-IgG患者平均年龄25岁,女性占44%。29例(54%)为孤立性横脊髓炎患者,10例(19%)为病毒/病毒后急性弛缓性脊髓炎患者。1名患者出现脑脊液寡克隆带增高(3%)。研究平均随访24个月,32名患者多次反复出现视神经炎、横向脊髓炎或急性播散性脑脊髓炎复发。相比于AQP4-IgG和MS,MOG-IgG患者前驱症状和并发急性播散性脑脊髓炎显著。磁共振显示,MOG-IgG患者 T 2信号异常局限于灰质,增强不明显;MOG-IgG 与AQP4-IgG纵向广泛T2病变无显著差异,但未见于MS患者;MOG-IgG与MS患者多发性脊髓病变和圆锥受累较多;约1/3的MOG-IgG 和AQP4-IgG患者行动依赖轮椅,但大部分MS患者不需要,MOG-IgG患者的预后优于AQP4-IgG患者。

MOG-IgG相关疾病的早期表现为脊髓炎,其中最常见的为急性弛缓性脊髓炎,疑似MOG-IgG人群因接受相应的临床及影像学检查。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2000666, encodeId=689f200066672, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sun Jun 09 19:17:00 CST 2019, time=2019-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650438, encodeId=d155165043878, content=<a href='/topic/show?id=b14384624a3' target=_blank style='color:#2F92EE;'>#脊髓炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84624, encryptionId=b14384624a3, topicName=脊髓炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06db24008155, createdName=xlysu, createdTime=Tue Mar 19 00:17:00 CST 2019, time=2019-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585384, encodeId=a3d81585384b5, content=<a href='/topic/show?id=2e681208016' target=_blank style='color:#2F92EE;'>#MOG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12080, encryptionId=2e681208016, topicName=MOG)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a85417178370, createdName=Boyinsh, createdTime=Wed Dec 26 08:17:00 CST 2018, time=2018-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615192, encodeId=2c06161519205, content=<a href='/topic/show?id=010c9506a3' target=_blank style='color:#2F92EE;'>#IgG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9506, encryptionId=010c9506a3, topicName=IgG)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c4f19588882, createdName=ms5768352621950538, createdTime=Wed Dec 26 08:17:00 CST 2018, time=2018-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=356308, encodeId=96b835630881, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Mon Dec 24 20:38:20 CST 2018, time=2018-12-24, status=1, ipAttribution=)]
    2019-06-09 yinhl1978
  2. [GetPortalCommentsPageByObjectIdResponse(id=2000666, encodeId=689f200066672, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sun Jun 09 19:17:00 CST 2019, time=2019-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650438, encodeId=d155165043878, content=<a href='/topic/show?id=b14384624a3' target=_blank style='color:#2F92EE;'>#脊髓炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84624, encryptionId=b14384624a3, topicName=脊髓炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06db24008155, createdName=xlysu, createdTime=Tue Mar 19 00:17:00 CST 2019, time=2019-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585384, encodeId=a3d81585384b5, content=<a href='/topic/show?id=2e681208016' target=_blank style='color:#2F92EE;'>#MOG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12080, encryptionId=2e681208016, topicName=MOG)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a85417178370, createdName=Boyinsh, createdTime=Wed Dec 26 08:17:00 CST 2018, time=2018-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615192, encodeId=2c06161519205, content=<a href='/topic/show?id=010c9506a3' target=_blank style='color:#2F92EE;'>#IgG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9506, encryptionId=010c9506a3, topicName=IgG)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c4f19588882, createdName=ms5768352621950538, createdTime=Wed Dec 26 08:17:00 CST 2018, time=2018-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=356308, encodeId=96b835630881, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Mon Dec 24 20:38:20 CST 2018, time=2018-12-24, status=1, ipAttribution=)]
    2019-03-19 xlysu
  3. [GetPortalCommentsPageByObjectIdResponse(id=2000666, encodeId=689f200066672, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sun Jun 09 19:17:00 CST 2019, time=2019-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650438, encodeId=d155165043878, content=<a href='/topic/show?id=b14384624a3' target=_blank style='color:#2F92EE;'>#脊髓炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84624, encryptionId=b14384624a3, topicName=脊髓炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06db24008155, createdName=xlysu, createdTime=Tue Mar 19 00:17:00 CST 2019, time=2019-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585384, encodeId=a3d81585384b5, content=<a href='/topic/show?id=2e681208016' target=_blank style='color:#2F92EE;'>#MOG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12080, encryptionId=2e681208016, topicName=MOG)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a85417178370, createdName=Boyinsh, createdTime=Wed Dec 26 08:17:00 CST 2018, time=2018-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615192, encodeId=2c06161519205, content=<a href='/topic/show?id=010c9506a3' target=_blank style='color:#2F92EE;'>#IgG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9506, encryptionId=010c9506a3, topicName=IgG)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c4f19588882, createdName=ms5768352621950538, createdTime=Wed Dec 26 08:17:00 CST 2018, time=2018-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=356308, encodeId=96b835630881, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Mon Dec 24 20:38:20 CST 2018, time=2018-12-24, status=1, ipAttribution=)]
    2018-12-26 Boyinsh
  4. [GetPortalCommentsPageByObjectIdResponse(id=2000666, encodeId=689f200066672, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sun Jun 09 19:17:00 CST 2019, time=2019-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650438, encodeId=d155165043878, content=<a href='/topic/show?id=b14384624a3' target=_blank style='color:#2F92EE;'>#脊髓炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84624, encryptionId=b14384624a3, topicName=脊髓炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06db24008155, createdName=xlysu, createdTime=Tue Mar 19 00:17:00 CST 2019, time=2019-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585384, encodeId=a3d81585384b5, content=<a href='/topic/show?id=2e681208016' target=_blank style='color:#2F92EE;'>#MOG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12080, encryptionId=2e681208016, topicName=MOG)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a85417178370, createdName=Boyinsh, createdTime=Wed Dec 26 08:17:00 CST 2018, time=2018-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615192, encodeId=2c06161519205, content=<a href='/topic/show?id=010c9506a3' target=_blank style='color:#2F92EE;'>#IgG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9506, encryptionId=010c9506a3, topicName=IgG)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c4f19588882, createdName=ms5768352621950538, createdTime=Wed Dec 26 08:17:00 CST 2018, time=2018-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=356308, encodeId=96b835630881, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Mon Dec 24 20:38:20 CST 2018, time=2018-12-24, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2000666, encodeId=689f200066672, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sun Jun 09 19:17:00 CST 2019, time=2019-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650438, encodeId=d155165043878, content=<a href='/topic/show?id=b14384624a3' target=_blank style='color:#2F92EE;'>#脊髓炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84624, encryptionId=b14384624a3, topicName=脊髓炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06db24008155, createdName=xlysu, createdTime=Tue Mar 19 00:17:00 CST 2019, time=2019-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585384, encodeId=a3d81585384b5, content=<a href='/topic/show?id=2e681208016' target=_blank style='color:#2F92EE;'>#MOG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12080, encryptionId=2e681208016, topicName=MOG)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a85417178370, createdName=Boyinsh, createdTime=Wed Dec 26 08:17:00 CST 2018, time=2018-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615192, encodeId=2c06161519205, content=<a href='/topic/show?id=010c9506a3' target=_blank style='color:#2F92EE;'>#IgG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9506, encryptionId=010c9506a3, topicName=IgG)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c4f19588882, createdName=ms5768352621950538, createdTime=Wed Dec 26 08:17:00 CST 2018, time=2018-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=356308, encodeId=96b835630881, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Mon Dec 24 20:38:20 CST 2018, time=2018-12-24, status=1, ipAttribution=)]
    2018-12-24 医者仁心5538

    学习了

    0

相关资讯

Neurology:见于视神经脊髓炎谱系疾病的皮质损害伴柔脑膜强化

27岁女性,表现为头痛伴双下肢无力和麻木2周。两年前,患者有难治性呃逆和呕吐,MRI上可见极后区病变

NEJM:CCR4单抗Mogamulizumab治疗1型人嗜T-淋巴病毒脊髓炎

Mogamulizumab 治疗可降低HTLV-1感染细胞以及炎症标志物水平,缓解患者痉挛及运动残疾,皮疹是最常见的不良事件

Nat Neurosci:上海交大自身免疫性脑脊髓炎新成果

来自上海交通大学医学院、美国克利夫兰诊所(Cleveland Clinic)的研究人员,在新研究中证实在NG2+神经胶质细胞中的Act1选择性介导了IL-17诱导的实验性自身免疫性脑脊髓炎(EAE)发病。这一研究发现在线发表在9月1日的《自然神经科学》(Nature Neuroscience)杂志上。【原文下载】 论文的通讯作者是美国克利夫兰诊所的李晓霞(Xiaoxia Li,音译)博士